MEDP Medpace Holdings Inc

$MEDP: after the class period, Medpace reported a 0.88 book-to-bill in Q1 2026 and shares fell about 22.6% Apr 23 to $393.42. Durbin is still complaint stage, no class certified, nothing to claim. Open Class Actions.

$MEDP looks like this is going to rip on earnings. got really tight for the last several weeks and looks great into the print tonight.

$MEDP: the Feb 10 drop is the number to know. Shares fell 15.9%, $530.35 to $446.05, after Medpace disclosed the highest backlog cancellations in over a year, plaintiffs allege. No class certified, nothing to claim. Open Class Actions.

$MEDP: an October 2025 claim is now central. Durbin alleges Medpace called Q3 revenue broad based, not a handful of studies, while pre-backlog leaned metabolic. No class certified, nothing to claim. Open Class Actions.

$MEDP Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $4.84 up 25.39% YoY • Reported revenue of $716M up 8.50% YoY

$MEDP Q3 EPS came in at 4.84 dollars vs 4.44 expected, revenue 716.0 million dollars, up 8.5%. The beat was mostly margin though, adjusted EBITDA margin hit 24.0% and net income margin widened to 19.2% from 16.8%. Bookings look better than the top line. New awards were 873.4 million dollars, up 10.6%, so book-to-bill ran about 1.22x, and backlog is back up to 3.17 billion dollars. Revenue growth slowed from 17.2% in Q2, and the full-year revenue guide midpoint actually sits a hair under consensus.

$MEDP Latest company news, Oct 21, 2026: Q3 revenue rose 8.5% to 716.0 million USD and net new business awards rose 10.6% to 873.4 million USD; diluted EPS was 4.84 USD. Medpace narrowed 2026 revenue guidance to 2.835-2.855 billion USD, raised the GAAP EPS range to 17.97-18.32 USD and approved a new buyback authorization of up to 1.0 billion USD. More details in our $MEDP stock hub. Not investment advice.

$MEDP Medpace, a clinical-trial contractor, sets $1.0B buyback, 5.4% of Oct 21, 2026 market value.